Nvidia (NVDA -0.85%) stock has soared by 870% since the start of 2023, catapulting its market capitalization to a whopping $3.5 trillion. Demand continues to exceed supply for the company's graphics processing units (GPUs) for the data center, which are the most powerful chips in the world for developing artificial intelligence (AI) models.Nvidia CEO Jensen Huang says new AI reasoning models, which spend more time thinking to produce accurate responses, require up to 1,000 times more computing capacity than ...

BEIJING, June 12, 2025 /PRNewswire/ -- Uxin Limited ("Uxin" or the "Company") (Nasdaq: UXIN), China's leading used car retailer, today announced its unaudited financial results for the quarter ended March 31, 2025.Highlights for the Quarter Ended March 31, 2025 Transaction volume was 8,264 units for the three months ended March 31, 2025, a decrease of 12.4% from 9,439 units in the last quarter and an increase of 103.6% from 4,058 units in the same period last year. Retail transaction volume was 7,545 units, ...

Former buy-side equity analyst covering Asia Pacific equities with a decade of experience under my belt. I employ a fundamental bottom-up approach with a macroeconomic overlay to identify stocks that are set to benefit from broader trends globally. I focus mainly on Financials, Industrials and Consumer Discretionary sectors. I started writing on Seeking Alpha to share my thoughts and shine a light on Asian equities listed in US markets. Asian equities (ex-China) are often times overlooked and under-allocate ...

UnitedHealth Group (UNH 2.27%) might want to change its stock ticker from "UNH" to "UGH." The latter better captures the feelings of the healthcare giant's shareholders in recent months.A string of problems has caused UnitedHealth Group's share price to plunge roughly 50% from the peak set in the fourth quarter of 2024. Some analysts have downgraded the stock, with HSBC recommending that investors reduce their holdings and slashing its price target. I have a different opinion, though. I think it's time to b ...

The markets saw history made earlier this month after President Donald Trump and Tesla (TSLA 0.07%) CEO Elon Musk had a disagreement over public policy via social media in front of the whole world. As a result, Tesla's stock lost about $150 billion in market capitalization in a single day (a new company record). The stock has recovered a bit of that 15% drop, but it is still down about 6% just since the end of May. It would seem that investors are getting increasingly pessimistic about Tesla's future. Its f ...

If the U.S. continues to impose AI semiconductor restrictions on China, then chipmaker Huawei will take advantage of its position in the world's second-largest economy, Nvidia CEO Jensen Huang told CNBC Thursday."Our technology is a generation ahead of theirs," Huang told CNBC at the sidelines of the Viva Technology conference in Paris.However, he warned that: "If the United States doesn't want to partake, participate in China, Huawei has got China covered, and Huawei has got everybody else covered."In the ...

Core Insights - Oracle's fourth-quarter results exceeded Wall Street expectations with earnings of $1.70 per share and sales of $15.9 billion, surpassing consensus estimates of $1.64 and $15.6 billion respectively [2] - The growth in cloud services, particularly cloud infrastructure, was a significant driver, with a 52% increase in Q4 and a projected 70% growth for fiscal year 2026 [2] - Following the positive results, Oracle's stock rose 8% to approximately $190 in extended trading [2] Financial Performance - Oracle's revenues have shown notable growth, with a 10.7% average annual increase over the last three years compared to 5.5% for the S&P 500 [8] - In the last 12 months, revenues grew 8.4% from $53 billion to $57 billion, while quarterly revenues increased 11% to $16 billion from $14 billion a year ago [8] - The company reported an operating income of $18 billion, resulting in a high operating margin of 30.8% [15] Valuation Metrics - Oracle's price-to-sales (P/S) ratio stands at 9.5, significantly higher than the S&P 500's 3.0, and its price-to-earnings (P/E) ratio is 43.7 compared to the benchmark's 26.4 [8] - The current P/S ratio of 9.5 is above Oracle's three-year average of 6.6, reflecting a justified increase in valuation due to strong growth prospects [12] Financial Stability - Oracle's balance sheet is described as neutral, with a debt figure of $104 billion and a market capitalization of $494 billion, resulting in a moderate debt-to-equity ratio of 21.0% [15] - Cash and cash equivalents amount to $11 billion out of total assets of $168 billion, leading to a cash-to-assets ratio of 6.7% [15] Resilience During Downturns - Oracle's stock has shown resilience during market downturns, outperforming the S&P 500 in several recent crises [11][16] - The stock fully recovered from significant declines during past market crises, indicating strong recovery potential [16]

Warren Buffett is the incredibly successful CEO of Berkshire Hathaway (BRK.A -0.53%) (BRK.B -0.55%). The stocks his company owns tend to receive plenty of extra attention from investors who want to mimic his investment approach (and match the level of returns Berkshire manages).There's a dichotomy today in the energy sector, in which Buffett owns two very different energy stocks. Which of these energy stocks is the better option for your portfolio?What does Warren Buffett do?Warren Buffett is the CEO of a c ...

A short-term setback gives investors a chance to buy this company, growing its share of a projected $1 trillion market.While the S&P 500 has mostly recovered from its drop earlier this year, most analysts have adjusted their earnings expectations lower due to rising trade tensions and economic uncertainty. As a result, many stocks still look expensive in today's market.Finding a bargain among them sometimes requires looking at stocks beaten down in recent months. Short-term challenges can often create great ...

After soaring to success in the early days of the COVID-19 pandemic, Moderna (MRNA 0.20%) experienced a reversal of fortune. The coronavirus vaccine maker has seen revenue plummet as demand for this flagship product -- Moderna's first to be approved -- has slipped. As a result, the stock fell out of favor with investors, leading to a decline of about 80% over the past three years.Since that time, the biotech company has delivered positive news, from the approval of a second product -- its respiratory syncyt ...